- Conditions
- Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, yttrium Y 90 ibritumomab tiuxetan
- Biological · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 58 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1441–1464
of 80,955
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mucopolysaccharidosis II
- Interventions
- AGT-182
- Drug
- Lead sponsor
- ArmaGen, Inc
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Oakland, California • Orange, California • Decatur, Georgia
- Conditions
- HIV Infections, Hepatic Insufficiency
- Interventions
- nevirapine
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 5
- States / cities
- Bakersfield, California • San Francisco, California • Albany, New York + 1 more
- Conditions
- Postoperative Delirium
- Interventions
- Omega-3 Ethyl Esters 4 g, Omega-3 Ethyl Esters 2 g
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Advanced Solid Tumor
- Interventions
- PTX-35
- Drug
- Lead sponsor
- Pelican Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Portland, Oregon • Austin, Texas • San Antonio, Texas
- Conditions
- Lupus Erythematosus
- Interventions
- ABT-199, Placebo
- Drug · Other
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 11
- States / cities
- Clearwater, Florida • DeBary, Florida • Miami, Florida + 7 more
- Conditions
- Connective Tissue Graft, Gum Recession
- Interventions
- Alloderm, MicroDerm
- Biological
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
- Interventions
- erlotinib hydrochloride, cisplatin, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, quality-of-life assessment
- Drug · Radiation · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 9
- States / cities
- Anchorage, Alaska • Miami, Florida • Albuquerque, New Mexico + 6 more
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- SAR3419
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Atopic Dermatitis
- Interventions
- Treatment with Halobetasol propionate 0.05% topical spray
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 13
- States / cities
- North Hollywood, California • Pasadena, California • Hialeah, Florida + 6 more
- Conditions
- Pregnancy Complications, Maternal Care Patterns, Patient Engagement
- Interventions
- Melanated Group Midwifery Care
- Behavioral
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 15 Years to 49 Years · Female only
- Enrollment
- 432 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- B-NHL, B-Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, B-precursor ALL, B-All, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma, B-Cell Leukemia, Acute Lymphoid Leukemia
- Interventions
- CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- PF-03084014
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 18
- States / cities
- Stanford, California • Chicago, Illinois • New Lenox, Illinois + 10 more
- Conditions
- Stress, Depression, Anxiety
- Interventions
- Polarity therapy
- Procedure
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Olympia, Washington
- Conditions
- COVID-19, Infectious Disease
- Interventions
- JCXH-221, Placebo
- Biological · Other
- Lead sponsor
- Immorna Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 4
- States / cities
- Hallandale, Florida • Savannah, Georgia • Lincoln, Nebraska + 1 more
- Conditions
- Uveitis
- Interventions
- Not listed
- Lead sponsor
- ChromoLogic, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hematopoietic Stem Cell Transplantation
- Interventions
- Tacrolimus, Methotrexate, Tocilizumab
- Drug
- Lead sponsor
- William R. Drobyski, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Schizophrenia
- Interventions
- EN3342
- Drug
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Marlton, New Jersey
- Conditions
- Sprain of Ankle
- Interventions
- Platelet rich plasma injection, Placebo Comparator: Placebo/Standard of Care
- Procedure
- Lead sponsor
- Albert Einstein Healthcare Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Uveitic Macular Edema
- Interventions
- Vamikibart, Sham
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 19 more
- Conditions
- Urticaria
- Interventions
- GDC-0853
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 7 more
- Conditions
- Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
- Interventions
- Early Glargine, Late Glargine, IV insulin infusion, IV fluid and electrolytes replacement
- Drug · Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Urinary Bladder Neoplasm, Neoplasm Metastasis
- Interventions
- Bempegaldesleukin, Nivolumab
- Biological
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 8
- States / cities
- San Francisco, California • Whittier, California • Aurora, Colorado + 5 more
- Conditions
- Suspected Central Nervous System Tumors
- Interventions
- Indocyanine Green (ICG), Intraoperative near-infrared (NIR)
- Drug · Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania